Conmed (CNMD) Tops Q4 EPS by 1c

Conmed (NYSE: CNMD) reported Q4 EPS of $1.07, $0.01 better than the analyst estimate of $1.06. Revenue for the quarter came in at $274 million versus the consensus estimate of $278.76 million.

GUIDANCE:

Conmed sees FY2022 EPS of $3.60-$3.85, versus the consensus of $3.74. Conmed sees FY2022 revenue of $1.075-1.125 billion, versus the consensus of $1.11 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Lennar Corp. (LEN) Misses Q3 EPS by 10c
• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
• Piper Sandler Reiterates Overweight Rating on Block Inc. (XYZ)